ImmuPharma (LON:IMM) Trading 34.1% Higher - Here's What Happened

Key Points

• ImmuPharma's stock surged by 34.1% on Tuesday, reaching a high of GBX 11.50 ($0.16) before closing at GBX 10.81 ($0.15), with trading volume increasing by 605% compared to its average.
• The company reported a net margin of 3,519.56% but a negative return on equity of 131.41%, indicating financial challenges despite its stock performance.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, being a novel treatment for Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) traded up 34.1% during trading on Tuesday . The stock traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). 53,526,668 shares were traded during mid-day trading, an increase of 605% from the average session volume of 7,597,544 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Trading Up 34.1%

The company has a 50 day moving average price of GBX 2.38 and a 200 day moving average price of GBX 2.70. The company has a market capitalization of £54.02 million, a price-to-earnings ratio of -1,214.61 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.